Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in manufacturing and distribution of invasive gynecologic technologies. The firm is focused on improving women's health and quality of life by providing access to minimally invasive, technologically advanced, and innovative solutions for early detection, treatment, and management of uterine conditions. The company delivers devices that treat the root causes of Abnormal Uterine Bleeding (AUB) in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and Disposable Hysteroscope. Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology. Symphion System is designed to transform the way you see and remove uterine fibroids and polyps.
Follow-Up Questions
Minerva Surgical Inc (UTRS)의 PER은 얼마입니까?
Minerva Surgical Inc의 PER은 0입니다
Minerva Surgical Inc의 CEO는 누구입니까?
Mr. Todd Usen은 2023부터 회사에 합류한 Minerva Surgical Inc의 President입니다.
UTRS 주식의 가격 성능은 어떻습니까?
UTRS의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Minerva Surgical Inc의 주요 사업 주제나 업종은 무엇입니까?
Minerva Surgical Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Minerva Surgical Inc의 시가총액은 얼마입니까?
Minerva Surgical Inc의 현재 시가총액은 $0입니다
Minerva Surgical Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Minerva Surgical Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다